Quantification of the dynamics of antibody response to malaria to inform sero-surveillance in pregnant women.
Antibodies
Longitudinal data
Malaria
PfAMA1
PfEBA175
PfMSP2
PfMSP3
PfVAR2CSA
Pregnancy
PvAMA1
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
05 Mar 2022
05 Mar 2022
Historique:
received:
07
09
2021
accepted:
28
02
2022
entrez:
6
3
2022
pubmed:
7
3
2022
medline:
9
3
2022
Statut:
epublish
Résumé
Malaria remains a major public health threat and tools sensitive to detect infections in low malaria transmission areas are needed to progress elimination efforts. Pregnant women are particularly vulnerable to malaria infections. Throughout pregnancy they access routine antenatal care, presenting a unique sentinel population to apply novel sero-surveillance tools to measure malaria transmission. The aim of this study was to quantify the dynamic antibody responses to multiple antigens during pregnancy so as to identify a single or multiple antibody response of exposure to malaria in pregnancy. This study involved a secondary analysis of antibody responses to six parasite antigens [five commonly studied merozoite antigens and the variant surface antigen 2-chondroitin sulphate A (VAR2CSA), a pregnancy-specific erythrocytic antigen] measured by enzyme-linked immunosorbent assay (ELISA) over the gestation period until delivery (median of 7 measurements/woman) in 250 pregnant women who attended antenatal clinics located at the Thai-Myanmar border. A multivariate mixture linear mixed model was used to cluster the pregnant women into groups that have similar longitudinal antibody responses to all six antigens over the gestational period using a Bayesian approach. The variable-specific entropy was calculated to identify the antibody responses that have the highest influence on the classification of the women into clusters, and subsequent agreement with grouping of women based on exposure to malaria during pregnancy. Of the 250 pregnant women, 135 had a Plasmodium infection detected by light microscopy during pregnancy (39% Plasmodium falciparum only, 33% Plasmodium vivax only and 28% mixed/other species), defined as cases. The antibody responses to all six antigens accurately identified the women who did not have a malaria infection detected during pregnancy (93%, 107/115 controls). Antibody responses to P. falciparum merozoite surface protein 3 (PfMSP3) and P. vivax apical membrane antigen 1 (PvAMA1) were the least dynamic. Antibody responses to the antigens P. falciparum apical membrane antigen 1 (PfAMA1) and PfVAR2CSA were able to identify the majority of the cases more accurately (63%, 85/135). These findings suggest that the combination of antibodies, PfAMA1 and PfVAR2CSA, may be useful for sero-surveillance of malaria infections in pregnant women, particularly in low malaria transmission settings. Further investigation of other antibody markers is warranted considering these antibodies combined only detected 63% of the malaria infections during pregnancy.
Sections du résumé
BACKGROUND
BACKGROUND
Malaria remains a major public health threat and tools sensitive to detect infections in low malaria transmission areas are needed to progress elimination efforts. Pregnant women are particularly vulnerable to malaria infections. Throughout pregnancy they access routine antenatal care, presenting a unique sentinel population to apply novel sero-surveillance tools to measure malaria transmission. The aim of this study was to quantify the dynamic antibody responses to multiple antigens during pregnancy so as to identify a single or multiple antibody response of exposure to malaria in pregnancy.
METHODS
METHODS
This study involved a secondary analysis of antibody responses to six parasite antigens [five commonly studied merozoite antigens and the variant surface antigen 2-chondroitin sulphate A (VAR2CSA), a pregnancy-specific erythrocytic antigen] measured by enzyme-linked immunosorbent assay (ELISA) over the gestation period until delivery (median of 7 measurements/woman) in 250 pregnant women who attended antenatal clinics located at the Thai-Myanmar border. A multivariate mixture linear mixed model was used to cluster the pregnant women into groups that have similar longitudinal antibody responses to all six antigens over the gestational period using a Bayesian approach. The variable-specific entropy was calculated to identify the antibody responses that have the highest influence on the classification of the women into clusters, and subsequent agreement with grouping of women based on exposure to malaria during pregnancy.
RESULTS
RESULTS
Of the 250 pregnant women, 135 had a Plasmodium infection detected by light microscopy during pregnancy (39% Plasmodium falciparum only, 33% Plasmodium vivax only and 28% mixed/other species), defined as cases. The antibody responses to all six antigens accurately identified the women who did not have a malaria infection detected during pregnancy (93%, 107/115 controls). Antibody responses to P. falciparum merozoite surface protein 3 (PfMSP3) and P. vivax apical membrane antigen 1 (PvAMA1) were the least dynamic. Antibody responses to the antigens P. falciparum apical membrane antigen 1 (PfAMA1) and PfVAR2CSA were able to identify the majority of the cases more accurately (63%, 85/135).
CONCLUSION
CONCLUSIONS
These findings suggest that the combination of antibodies, PfAMA1 and PfVAR2CSA, may be useful for sero-surveillance of malaria infections in pregnant women, particularly in low malaria transmission settings. Further investigation of other antibody markers is warranted considering these antibodies combined only detected 63% of the malaria infections during pregnancy.
Identifiants
pubmed: 35248084
doi: 10.1186/s12936-022-04111-y
pii: 10.1186/s12936-022-04111-y
pmc: PMC8897879
doi:
Substances chimiques
Antibodies, Protozoan
0
Antigens, Protozoan
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
75Subventions
Organisme : National Health and Medical Research Council
ID : 1196068
Organisme : National Health and Medical Research Council
ID : 1166753
Organisme : National Health and Medical Research Council
ID : 1134989
Organisme : National Health and Medical Research Council
ID : 1134989
Organisme : National Health and Medical Research Council
ID : 1134989
Organisme : National Health and Medical Research Council
ID : 1173046
Informations de copyright
© 2022. The Author(s).
Références
Infect Immun. 2001 Dec;69(12):7487-92
pubmed: 11705924
J Infect Dis. 2012 Nov 15;206(10):1612-21
pubmed: 22966126
N Engl J Med. 2008 Dec 11;359(24):2545-57
pubmed: 19064624
Lancet Infect Dis. 2012 Jan;12(1):75-88
pubmed: 22192132
Infect Immun. 2018 Aug 22;86(9):
pubmed: 29986889
Lancet Glob Health. 2019 Dec;7(12):e1695-e1705
pubmed: 31708150
PLoS One. 2012;7(1):e29550
pubmed: 22238621
Lancet Infect Dis. 2018 Apr;18(4):e107-e118
pubmed: 29396010
J Leukoc Biol. 2017 Apr;101(4):913-925
pubmed: 27837017
Trans R Soc Trop Med Hyg. 1997 May-Jun;91(3):256-62
pubmed: 9231189
Front Microbiol. 2019 Jan 16;9:3300
pubmed: 30700984
J Infect Dis. 2017 Oct 17;216(7):887-898
pubmed: 28973483
Trends Parasitol. 2019 Sep;35(9):677-686
pubmed: 31395496
Int Psychogeriatr. 2006 Dec;18(4):667-80
pubmed: 16640798
PLoS One. 2014 Jun 06;9(6):e98577
pubmed: 24905223
Trop Med Int Health. 2007 Feb;12(2):209-18
pubmed: 17300627
Malar J. 2011 Oct 28;10:321
pubmed: 22035448
Malar J. 2015 Oct 05;14:388
pubmed: 26437860
Trans R Soc Trop Med Hyg. 1991 Jul-Aug;85(4):424-9
pubmed: 1836685
Comput Methods Programs Biomed. 2011 Dec;104(3):e112-21
pubmed: 21708413
BMC Med. 2014 Sep 09;12:150
pubmed: 25199532
Nature. 1998 Oct 29;395(6705):851-2
pubmed: 9804416
Trends Parasitol. 2014 Feb;30(2):85-94
pubmed: 24388420
Lancet. 2004 Jan 24;363(9405):283-9
pubmed: 14751701
Nat Med. 2020 May;26(5):741-749
pubmed: 32405064
PLoS Med. 2010 Jan 26;7(1):e1000221
pubmed: 20126256
Semin Perinatol. 2019 Aug;43(5):282-290
pubmed: 30979598
Infect Immun. 2015 Feb;83(2):646-60
pubmed: 25422270
Infect Immun. 2009 Mar;77(3):1165-74
pubmed: 19139189
N Engl J Med. 2014 Jun 5;370(23):2211-8
pubmed: 24897084
Proc Natl Acad Sci U S A. 2015 Aug 11;112(32):E4438-47
pubmed: 26216993
PLoS One. 2012;7(12):e52939
pubmed: 23300828
PLoS Med. 2007 Nov 13;4(11):e320
pubmed: 18001147
Clin Infect Dis. 2010 Oct 15;51(8):e50-60
pubmed: 20843207
PLoS Med. 2011 Jan 25;8(1):e1000396
pubmed: 21311583
Malar J. 2016 Nov 4;15(1):529
pubmed: 27809852
Emerg Infect Dis. 2019 Oct;25(10):1851-1860
pubmed: 31538557
F1000Prime Rep. 2014 Nov 04;6:100
pubmed: 25580254
J Infect Dis. 2009 Nov 15;200(10):1509-17
pubmed: 19848588
Lancet. 1999 Aug 14;354(9178):546-9
pubmed: 10470698
PLoS One. 2011;6(11):e28126
pubmed: 22140521
Mol Ecol. 2013 Jan;22(2):273-85
pubmed: 23121253
BMC Med. 2021 Apr 27;19(1):98
pubmed: 33902567
J Mol Biol. 2010 Apr 2;397(3):826-34
pubmed: 20109466
BMC Med. 2020 Jan 16;18(1):14
pubmed: 31941488